Home LiteratureArticle Details
PMID: 7173321 Published · ppublish English Journal Article

Phencyclidine-like discriminative stimuli of (+)- and (-)-N-allylnormetazocine in rats.

European journal of pharmacology ·Vol. 84 ·No. 3-4 ·1982-10-22 ·Pages 225-8

Shannon HE

Abstract

The phencyclidine(PCP)-like discriminative stimulus properties of the (+)- and (-)-isomers of the prototypic sigma-receptor agonist N-allylnormetazocine (NANM) were evaluated in rats trained to discriminate between saline and 3.0 mg/kg of PCP. The rats were trained under a FR5 schedule of stimulus-shock termination. Both (+)- and (-)-NANM produced PCP-like stimuli and were approximately one-half and one-sixth, respectively, as potent as PCP. The two isomers were equipotent in decreasing response rates. None of the effects of either (+)- or (-)-NANM were antagonized by naloxone. These results demonstrate that the PCP-like effects of NANM exhibit stereoselectivity but not stereospecificity and are additional evidence that the common actions of PCP and NANM are mediated by sigma-receptors.

MeSH Terms
Animals Discrimination Learning/drug effects Discrimination, Psychological/drug effects Male Naloxone/pharmacology Phenazocine/analogs & derivatives,pharmacology Phencyclidine/pharmacology Rats Rats, Inbred F344 Reinforcement Schedule Stereoisomerism
Chemicals
Naloxone SK&F 10047 Phenazocine Phencyclidine
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Shannon H E
Article Info
Journal
European journal of pharmacology
Abbr.
Eur J Pharmacol
ISSN
0014-2999
Published
1982-10-22
Pages
225-8
Language
English
Region
Netherlands
NLM ID
1254354
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]